Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Hidradenitis Suppurativa Tied to Higher Mortality

David Douglas  |  February 24, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa (HS) is associated with a significantly increased risk of adverse cardiovascular (CV) outcomes and all-cause mortality, according to Danish researchers. HS is a chronic, inflammatory skin disease and is most common in women. It is typically diagnosed after long delays, Dr. Alexander Egeberg of the University of Copenhagen and colleagues…

Apremilast Proves Effective for PsA with Skin Involvement

Michele B. Kaufman, PharmD, BCGP  |  February 24, 2016

A recent Phase 3 clinical trial found apremilast safe and effective for treating patients with active psoriatic arthritis and skin symptoms who found conventional and biologic DMARDs ineffective…

U.S. & EU Regulators Urge Indian Drug Companies to Step Up Standards

Zeba Siddiqui  |  February 23, 2016

MUMBAI (Reuters)—U.S. and EU drug regulators called upon India’s pharmaceutical sector on Tuesday to step up efforts to improve manufacturing standards and ensure the reliability of data if it is to maintain its dominance in the generic drugs industry. India’s $15 billion pharmaceutical industry, an increasingly important global supplier of cheaper generic medicines, has been…

Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial

Reuters Staff  |  February 23, 2016

(Reuters)—Amgen Inc. and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study. The topline results, from a Fracture study in postmenopausal women with osteoporosis (FRAME), showed that the drug romosozumab met a…

Dermatology & Immunology: Skin Issues Can Present Challenges

Thomas R. Collins  |  February 23, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

U.S. Proposes Hike in Medicare Advantage Payments; Insurer Shares Rise

Caroline Humer  |  February 22, 2016

NEW YORK (Reuters)—The U.S. government on Friday proposed raising payments by 1.35% on average next year to the health insurers who offer Medicare Advantage health benefits to elderly and disabled Americans. Payments to insurers will vary under the 2017 Medicare Advantage proposal, based on the region the plans are sold and on the size of…

Scientists Find How ‘Superbugs’ Build Their Defenses

Kate Kelland  |  February 22, 2016

LONDON (Reuters)—Scientists in Britain have found how drug-resistant bacteria build and maintain a defensive wall—a discovery that paves the way for the development of new drugs to break through the barrier and kill the often deadly “superbugs.” In recent decades, bacteria resistant to multiple drugs, such as methicillin-resistant Staphylococcus aureus (MRSA) or Clostridium difficile, have…

Insight into Crosstalk Between Bone & Immune Systems

Lara C. Pullen, PhD  |  February 22, 2016

Osteoimmunology is an emerging field that focuses on the interaction between bone and the immune system. CD4+ T cells play an important role in the bone marrow and modulate the differentiation of bone-resorbing osteoclasts. This article reviews the role of CD4+ T cells as an osteoclastogenic population in inflammatory bowel disease…

Los Angeles Hospital Paid Hackers $17,000 Ransom in Bitcoins

Reuters Staff  |  February 20, 2016

(Reuters)—The president of Hollywood Presbyterian Medical Center said on Wednesday that his hospital paid hackers a ransom of $17,000 in bitcoins to regain control of their computer systems after a cyber attack. Allen Stefanek said in a statement that paying the ransom was the “quickest and most efficient way” of regaining access to the affected…

Route of Iron Replacement Doesn’t Impact IBD Activity, Quality of Life

Laura Newman  |  February 20, 2016

NEW YORK (Reuters Health)—The route of iron replacement therapy alters the gut microbiome and metabolomics in patients with inflammatory bowel disease (IBD), but the route is unrelated to disease activity and quality of life, according to a new study. “Crohn’s disease patients are extremely fragile to disturbances and one might speculate about consequences in long-term…

  • « Previous Page
  • 1
  • …
  • 521
  • 522
  • 523
  • 524
  • 525
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences